Skip to content

Artificial intelligence in cardiovascular disease—— prediction and analysis system in acute intensive patients based on artificial intelligence

Artificial intelligence in cardiovascular diseases—— prediction and decision system in critical or emergent illness based on artificial intelligence

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104108
Enrollment
Unknown
Registered
2025-06-11
Start date
2024-09-09
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intensive acute cardiovascular diseases including heart failure, acute aortic syndrome, atrial fibrillation with acute coronary syndrome/ percutaneous coronary intervention, myocarditis, acute malignant ventricular arrhythmia

Interventions

Sponsors

Fuwai Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria according to definition as follows: 1.Acute heart failure: discharge diagnosed with "acute heart failure" or "acute on chronic heart failure"; 2.Myocarditis: The discharge diagnosis includes "myocarditis," "dilated cardiomyopathy," or "inflammatory cardiomyopathy"; 3.aortic syndrome: discharge diagnosed with ‘aortic dissection’; 4.atrial fibrillation with acute coronary syndrome/percutaneous coronary intervention: discharge diagnosed with "acute coronary syndrome" or "unstable angina" or "percutaneous coronary intervention" complicated with "atrial fibrillation"; 5. malignant ventricular arrhythmia: discharge diagnosed with "ventricular arrhythmia"; (2)aged>=18, all genders are included; (3) Patients have signed consent to participate this study.

Exclusion criteria

Exclusion criteria: 1.Participation in another investigational drug study; 2.participant refused to sign the consent. 3.participants who are incapacity or restricted capacity to react; 4.other conditions which researchers consider participant is not suitable for this study.

Design outcomes

Primary

MeasureTime frame
all-cause mortality;Aorta-related death;Aorta-related adverse events;major adverse cardiovascular events;cardiovascular death;Recurrent malignant ventricular arrhythmia;

Secondary

MeasureTime frame
thrombosis/stroke;recurrent myocardial infarction;unplanned revascularization;major bleeding defined as BARC>= class 3;cardiovascular mortality;heart failure rehospitalization;Re-hospitalization due to cardiac event;

Countries

China

Contacts

Public ContactYanmin Yang

Fuwai Hospital, Chinese Academy of Medical Sciences

yyminfuwai@163.com+86 178 1201 3496

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026